Brief: Novartis Says FDA Approves Rhapsido (Remibrutinib) As First Treatment For Symptomatic Dermographism
07/10/2026 16:48
BRIEF-Novartis Says FDA Approves Rhapsido (Remibrutinib) As First Treatment For Symptomatic Dermographism Oct 7 (Reuters) - NOVARTIS AG NOVN.S:
NOVARTIS RHAPSIDO® (REMIBRUTINIB) RECEIVES FDA APPROVAL AS FIRST TREATMENT FOR SYMPTOMATIC DERMOGRAPHISM (SD), EXPANDING ITS USE BEYOND CHRONIC SPONTANEOUS URTICARIA (CSU)
FDA APPROVES RHAPSIDO (REMIBRUTINIB) AS FIRST TREATMENT FOR SYMPTOMATIC DERMOGRAPHISM
RHAPSIDO ONLY APPROVED TREATMENT FOR BOTH CSU AND SD WHEN ANTIHISTAMINES FAIL
29.3% OF RHAPSIDO PATIENTS ACHIEVE COMPLETE RESPONSE FROM HIVES AT WEEK 12 VERSUS 14.0% PLACEBO
RHAPSIDO SAFETY PROFILE IN SD CONSISTENT WITH CSU; NO ROUTINE LAB MONITORING REQUIRED
Source text: ID:nGNE2wg8SD
Further company coverage: NOVN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Novartis AG
See all newsNovartis' breast cancer drug cuts risk of death by 19% after six years, data shows
Novartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx